Emergent BioSolutions Inc. announced the appointment of Dr. Karen L. Smith, M.D., Ph.D. as chief medical officer with responsibility for leading and further establishing Emergent’s global integrated capability in clinical development, medical affairs, and regulatory affairs.
GAITHERSBURG, Md., April 21, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Dr. Karen L. Smith, M.D., Ph.D. as chief medical officer with responsibility for leading and further establishing Emergent’s global integrated capability in clinical development, medical affairs, and regulatory affairs. Dr. Smith and her teams will work in partnership with the business units to advance the company’s portfolio of products in development. She will be a member of the executive management team reporting to the president and chief executive officer.
Robert G. Kramer Sr., president and chief executive officer at Emergent BioSolutions, stated, “On behalf of the management team, I am pleased to welcome Karen to Emergent. Karen’s broad experience and in-depth knowledge in diverse therapeutic areas complement Emergent’s business unit structure with our wide range of products and programs in various stages of development. I believe Karen’s leadership will enhance our strategic direction and operational effectiveness, and most importantly, increase our potential impact on the lives of patients across the globe.”
“I am proud to be joining a company whose simple mission – to protect and enhance life – seeks to address such complex public health issues that have a profound effect on human life,” said Dr. Smith. “I look forward to working together with the dedicated Emergent team whose actions are centered on delivering peace of mind through our products and services and in partnership with governments, healthcare providers, academia, non-government organizations, and others.”
Dr. Smith has previously served as chief medical officer for Jazz Pharmaceuticals and has held senior executive positions at pharmaceutical and biotechnology companies, including Allergan, AstraZeneca, Bristol-Myers Squibb, and most recently as president and CEO of Medeor Therapeutics, Inc. Her experience covers several therapeutic areas such as oncology, rare disease, cardiology, dermatology, and neuroscience; and includes a successful track record of acquisitions, divestitures, and partnership deals. Dr. Smith currently serves as a director for Acceleron Pharmaceuticals, Antares Pharma, and Sangamo Therapeutics. Dr. Smith holds an M.D. in Cardiology, a Ph.D. in Molecular Oncology, an MBA, and a Master’s in Law.
About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.
Media Contact:
Miko B. Neri
Senior Director, Corporate Communications
240-631-3392
NeriM@ebsi.com
Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
BurrowsR@ebsi.com
